Bayer and Regeneron have initiated a head-to-head Phase III study of the VEGF Trap-Eye versus Genentech's Lucentis. Both therapies treat age-related macular degeneration, or Wet AMD. The companies expect to enroll 1,200 subjects at 200 sites. The primary endpoint of the study is the proportion of patients treated with the VEGF Trap-Eye who maintain or improve vision at the end of one year, compared to Lucentis patients. VEGF Trap-Eye can be taken less frequently than Lucentis, which Bayer and Regeneron hope will give it an edge in the market. Lucentis has already been through another head-to-head trial with Visudyne and came out on top.
- check out this release